mRNA Technology Could Replace GLP-1 Injections by Teaching the Body to Make Its Own GLP-1 Protein | Research

The takeaway

A novel mRNA approach that instructs the body to produce GLP-1-Fc protein achieved blood sugar reduction comparable to dulaglutide in diabetic mice, with sustained effects and no tissue damage.

Comparable efficacy to dulaglutide
The mRNA-produced GLP-1-Fc protein achieved similar glucose reduction as the established GLP-1 drug, with sustained effects after single and repeated doses in diabetic mice

What the researchers found

The GLP-1-Fc mRNA successfully encoded and produced GLP-1-Fc protein both in cell culture (HEK293T cells) and in living mice. In db/db diabetic mice, the mRNA treatment produced significantly higher GLP-1-Fc protein levels than controls, effectively reduced blood glucose after single and repeated administrations, and increased GLP-1 receptor expression. The glucose-lowering efficacy was comparable to dulaglutide (the existing GLP-1 protein drug). Intraperitoneal delivery did not cause tissue damage.

Why it matters

Current GLP-1 drugs require regular injections of manufactured peptides, which are expensive and complex to produce. An mRNA-based approach could fundamentally change GLP-1 therapy by letting the body produce its own therapeutic peptide — potentially offering longer-lasting effects, simpler manufacturing, and lower costs. This represents the convergence of mRNA technology (proven in vaccines) with the peptide therapeutics field.

How the study worked

GLP-1-Fc mRNA was generated using in vitro transcription and fusion protein technology. Protein expression was confirmed in HEK293T cells via Western blot and ELISA. The mRNA and dulaglutide were then administered to both normal (C57BL/6J) and diabetic (db/db) mice. Researchers measured protein levels (ELISA), GLP-1 receptor activity (cAMP assay), blood glucose, receptor expression (immunofluorescence), and tissue safety (H&E staining) after single and repeated doses.

What this study cannot tell us

This is a preclinical mouse study, and translation to humans remains uncertain. The db/db mouse is a specific genetic model of diabetes that may not reflect the complexity of human type 2 diabetes. Duration of protein expression and long-term safety were not fully characterized. Intraperitoneal delivery used in mice is not a standard clinical route. The study did not compare manufacturing costs or scalability to existing peptide production.

How to read the evidence

This is a preclinical proof-of-concept study in cell culture and mouse models. While the results are promising and well-characterized, no human data exists. The technology is at an early stage of development.

When this study was published

Published in 2025, this study represents cutting-edge work at the intersection of mRNA technology and peptide therapeutics, building on the mRNA platform validated during COVID vaccine development.

The bigger picture

This study bridges two of the most transformative areas in modern medicine: mRNA therapeutics and GLP-1 receptor agonists. While mRNA technology proved its potential with COVID vaccines, applying it to chronic disease management through sustained peptide production is a significant conceptual leap. If mRNA-based GLP-1 delivery proves viable in humans, it could disrupt the current GLP-1 drug market — one of the fastest-growing segments in pharmaceutical history — by offering a fundamentally different delivery paradigm.

Questions still open

How long does a single mRNA dose sustain therapeutic GLP-1-Fc protein levels compared to weekly peptide injections?
Could this mRNA approach be adapted for subcutaneous delivery that would be practical for human patients?
Would repeated mRNA dosing over months or years trigger immune responses that reduce efficacy?

Common questions

How does mRNA-based GLP-1 therapy differ from current GLP-1 drugs?

Current GLP-1 drugs like semaglutide (Ozempic) and dulaglutide (Trulicity) are manufactured peptide proteins that you inject regularly. The mRNA approach instead delivers instructions that tell your own cells to produce the therapeutic GLP-1 protein — similar to how mRNA COVID vaccines work. This could potentially offer longer-lasting effects and simpler manufacturing.

Could this replace Ozempic or Wegovy?

It's far too early to say. This technology has only been tested in mice. Translating mRNA-based GLP-1 delivery to humans would require years of additional research, safety testing, and clinical trials. However, the concept of the body producing its own therapeutic GLP-1 peptide is an exciting direction that could eventually offer an alternative to current injection-based therapies.

Read the original research

Enhancing GLP-1 expression via IVT mRNA and fusion protein technology for diabetes therapy.

Journal of pharmaceutical sciences, 114(7), 103829

View on PubMed ↗Publisher’s paper ↗

Citation

Wu, Xiaoying; Qiao, Jingtao; Xiao, Fei; Guo, Lixin. (2025). Enhancing GLP-1 expression via IVT mRNA and fusion protein technology for diabetes therapy.. Journal of pharmaceutical sciences, 114(7), 103829. https://doi.org/10.1016/j.xphs.2025.103829